Simponi – FDA Approval for 2 New Indications

The U.S. Food and Drug Administration last week approved SIMPONI ARIA® (golimumab) for the treatment of adult patients with active psoriatic arthritis (PsA) and for the treatment of adult patients with active ankylosing spondylitis (AS). According to Janssen’s announcement, SIMPONI ARIA® is now approved for the treatment of adults with psoriatic arthritis, ankylosing spondylitis and moderately to severely active rheumatoid arthritis.
Janssen will work with payers, providers and pharmacy benefit managers to ensure SIMPONI ARIA® is broadly accessible for patients and that the cost for payers is competitive with currently available biologic therapies for PsA and AS.
For additional information, please contact United Rheumatology or your local Janssen representative.

Become a Member

Whether you have an established practice, you’re fresh out of your fellowship, or you’re a hospital-based rheumatologist considering private practice, United Rheumatology offers the resources and services you need to advance your career and your clinic.


Find a UR Rheumatologist Near Me

© 2023 United Rheumatology